Ibrance 125 mg 21 tab*شرائط* "(PSP)"

Indications: HR+/HER2- locally advanced or metastatic breast cancer: In combination with an aromatase inhibitor as initial endocrine-based therapy. In combination with fulvestrant in patients who have received prior endocrine therapy.